SkinHealth Systems Q1 Revenue Falls 6.7% to $64.9M; Adjusted EBITDA Rises 16%
SkinHealth Systems reported Q1 2026 net sales of $64.9 million, down 6.7% year-over-year, driven by declines in delivery system and consumables sales. Net loss narrowed to $6.6 million while adjusted EBITDA climbed to $8.5 million as operating expenses fell 24%.
1. First Quarter Financial Results
SkinHealth Systems delivered Q1 2026 net sales of $64.9 million, down from $69.6 million in Q1 2025. Delivery systems sales fell to $18.5 million from $20.2 million and consumables sales declined to $46.4 million from $49.4 million year-over-year.
2. Operational and Margin Trends
Gross margin slipped to 68.5% from 69.8%, while adjusted gross margin edged up to 72.2% from 71.9%. The company placed 746 delivery systems, down from 862, but grew its active install base to 36,419 systems from 35,014.
3. Profitability Improvements
Operating expenses decreased to $46.2 million from $60.6 million, driven by lower personnel and marketing spend. As a result, net loss narrowed to $6.6 million from $10.1 million and adjusted EBITDA rose to $8.5 million from $7.3 million.
4. Revised 2026 Guidance
For Q2 2026, SkinHealth projects net sales of $72–$77 million and adjusted EBITDA of $11–$13 million. Full-year 2026 guidance was cut to $280–$295 million in net sales and $35–$45 million in adjusted EBITDA.